NewAmsterdam Pharma (NAMS) Common Equity (2021 - 2026)
NewAmsterdam Pharma (NAMS) posted Common Equity of $665.2 million for Q1 2026, down 2.66% sequentially from $683.4 million in Q4 2025, and down 14.43% YoY from $777.4 million in Q1 2025.
NewAmsterdam Pharma (NAMS) Common Equity (2021 - 2026) Analysis & Trends
NewAmsterdam Pharma has reported Common Equity for 6 years, with the latest figure at $665.2 million in Q1 2026.
- Quarterly Common Equity fell 14.43% year-over-year to $665.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $665.2 million (down 14.43% YoY) and the FY2025 annual result came in at $683.4 million, down 9.78% from the prior year.
- Common Equity eased to $665.2 million in Q1 2026 per NAMS's latest filing, from $683.4 million in the prior quarter.
- Over five years, Common Equity peaked at $778.5 million in Q2 2025 and troughed at $288.4 million in Q4 2023.
- A 5-year average of $532.5 million and a median of $453.1 million in 2022 frame the typical range for Common Equity.
- The sharpest annual moves came in 2022 and 2023: Common Equity surged 767.87% in 2022, then plunged 41.66% in 2023.
- Over 5 years, Common Equity stood at $494.3 million in 2022, then slumped by 41.66% to $288.4 million in 2023, then surged by 162.66% to $757.5 million in 2024, then slipped by 9.78% to $683.4 million in 2025, then fell by 2.66% to $665.2 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $665.2 million, $683.4 million, and $728.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | NewAmsterdam Pharma | 3.17 Bn | 3.17 Bn | - | 631.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 631.42 Mn |
| Mar 31, 2026 | 665.22 Mn |
| Dec 31, 2025 | 683.43 Mn |
| Sep 30, 2025 | 728.07 Mn |
| Jun 30, 2025 | 778.50 Mn |
| Mar 31, 2025 | 777.36 Mn |
| Dec 31, 2024 | 757.50 Mn |
| Sep 30, 2024 | 378.86 Mn |
| Jun 30, 2024 | 387.44 Mn |
| Mar 31, 2024 | 411.80 Mn |
| Dec 31, 2023 | 288.39 Mn |
| Sep 30, 2023 | 331.84 Mn |
| Jun 30, 2023 | 373.34 Mn |
| Mar 31, 2023 | 398.41 Mn |
| Dec 31, 2022 | 494.33 Mn |
| Dec 31, 2021 | 56.96 Mn |